8-K: Apogee Therapeutics Doses First Patient in Phase 2 APEX Trial Part B, Exceeds Enrollment in Part A

Apogee Therapeutics has announced the dosing of the first patient in Part B of its Phase 2 APEX trial for APG777 in atopic dermatitis, while also reporting that enrollment for Part A exceeded expectations.

Summary

• Apogee Therapeutics has initiated Part B of its Phase 2 APEX clinical trial for APG777, a monoclonal antibody targeting IL-13, in patients with moderate-to-severe atopic dermatitis.
• The company also announced that enrollment for Part A of the trial was completed, exceeding the target of approximately 110 patients with a total of 123 patients randomized.
• Part A of the trial randomized patients 2:1 to APG777 versus placebo, while Part B will randomize approximately 280 patients 1:1:1:1 to high, medium, or low dose APG777 versus placebo.
• The primary endpoint for both parts of the study is the mean percentage change in Eczema Area and Severity Index (EASI) score from baseline at week 16.
• Secondary endpoints include EASI-75 and Investigators Global Assessment 0/1 at week 16.
• Apogee anticipates releasing Part A 16-week induction data in mid-2025, maintenance data in the first half of 2026, and Part B 16-week data in the second half of 2026.
• The company plans to initiate a Phase 1b trial in asthma in the first half of 2025, followed by a Phase 2b trial in asthma in the second half of 2025, and a Phase 2 trial in eosinophilic esophagitis (EoE) in 2026.
• Apogee also plans to evaluate APG777 in combination with other investigational therapies, starting with a Phase 1b trial of APG777 and APG990 in 2025, with results expected in the second half of 2026.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful enrollment in Part A of the trial, the initiation of Part B, and the potential for APG777 to be a best-in-class treatment. The company is also planning to expand into other indications and explore combination therapies. However, there are risks and uncertainties associated with clinical trials and regulatory approvals.

Positives

• Enrollment for Part A of the APEX trial exceeded the target, indicating strong patient and investigator interest.
• The trial design allows for a seamless transition from Part A to Part B, potentially accelerating the clinical development process.
• APG777 has shown promising preclinical results, with the potential to exceed lebrikizumab exposures and reduce injection frequency.
• The company has a broad pipeline and is exploring multiple indications for APG777, including asthma and EoE.
• The company is also exploring combination therapies to potentially enhance efficacy and safety.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties, including those related to clinical trial outcomes, regulatory approvals, and financial resources.
• There is a risk that actual results could differ materially from the company's expectations.
• Global macroeconomic conditions and related volatility could impact the company's operations and financial performance.
• The relationship between preclinical study results and clinical study results is unpredictable.
• There are risks associated with the timing and likelihood of regulatory filings and approvals.

Future Outlook

Apogee plans to advance the development of APG777 in multiple indications, including asthma and EoE, and to explore combination therapies. The company anticipates several data readouts from its clinical trials in 2025 and 2026.

Management Comments

• Carl Dambkowski, M.D., Chief Medical Officer of Apogee, stated that the strong patient and investigator enthusiasm underscores the potential of APG777 to address the need for safe, effective treatment options.
• Management believes that APG777 is modeled to exceed lebrikizumab exposures by 30-40% with potential for improved clinical responses, as well as approximately half the number of injections during induction and 70-90% fewer injections in maintenance compared to currently available therapies.

Industry Context

This announcement is significant in the context of the competitive landscape for atopic dermatitis treatments, where there is a need for therapies with improved efficacy, reduced injection burden, and better disease control. Apogee is positioning APG777 as a potential best-in-class treatment by targeting IL-13 and optimizing half-life and dosing.

Comparison to Industry Standards

• Apogee is comparing APG777 to lebrikizumab, a known IL-13 inhibitor, stating that APG777 is modeled to exceed lebrikizumab exposures by 30-40%.
• The company is also highlighting the potential for reduced injection frequency compared to currently available therapies, which is a key differentiator in the market.
• The trial design, combining Phase 2a and 2b into a single protocol, is aimed at streamlining the clinical development process, which is a common strategy to accelerate time to market.
• The company is also exploring combination therapies, which is a growing trend in the industry to enhance efficacy and safety.

Stakeholder Impact

• Shareholders may view this announcement positively due to the progress in clinical development and the potential for APG777 to be a successful product.
• Patients with atopic dermatitis may benefit from the development of a new treatment option with potentially improved efficacy and reduced injection burden.
• Employees of Apogee may be motivated by the progress in clinical trials and the potential for the company to grow.
• The company's suppliers and partners may benefit from the continued development of APG777.

Next Steps

• Apogee will continue to enroll patients in Part B of the Phase 2 APEX trial.
• The company will analyze the data from Part A of the trial and release 16-week induction data in mid-2025.
• Apogee will initiate a Phase 1b trial in asthma in the first half of 2025.
• The company will initiate a Phase 2b trial in asthma in the second half of 2025.
• Apogee will launch a Phase 2 trial in EoE in 2026.
• The company will initiate a Phase 1b trial of APG777 and APG990 in 2025.

Key Dates

Keywords

APG777, Atopic Dermatitis, Clinical Trial, Phase 2, Monoclonal Antibody, IL-13, EASI Score, Asthma, Eosinophilic Esophagitis, APEX Trial